Vor Bio
↗Boston, USA
Vor Bio is a clinical-stage biotechnology company that has recently repositioned its focus toward transforming the treatment of autoimmune diseases. The company is primarily focused on the global development and commercialization of telitacicept, a novel dual-target BAFF/APRIL inhibitor.
Following a strategic pivot in 2025, the company secured global rights (excluding China, Hong Kong, Macau, and Taiwan) to telitacicept through a licensing agreement with RemeGen. Vor Bio is currently advancing this asset through Phase 3 clinical trials for indications such as generalized myasthenia gravis and primary Sjögren's disease.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital, Venrock Healthcare Capital Partners
STOCK
Exchange:NASDAQ
Ticker:VOR
Market Cap:$0.9B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Fusion protein
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:RemeGen Co., Ltd. (Exclusive global license for telitacicept outside of China/HK/Macau/Taiwan)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Jean-Paul Kress - CEO and Chairman
Dallan Murray - Chief Commercial Officer
Board Members:Andrew Levin, Wouter Joustra
LINKS
Website:vorbio.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Vor Bio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Vor Bio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.